Trade Receivables |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Receivables [Abstract] | |
| Trade Receivables | Trade Receivables Product Sales Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and peramivir. At June 30, 2025 and December 31, 2024, receivables, net of reserves, related to sales of ORLADEYO were $87,575 and $76,282, respectively. At June 30, 2025 and December 31, 2024, receivables related to sales of peramivir were $381 and $564, respectively. At June 30, 2025, there was $10,403 of accounts receivable, net of reserves, included in current assets held for sale. See “Note 2—Assets and Liabilities Held for Sale” for further details. Collaborations At June 30, 2025 and December 31, 2024 receivables from collaborations related to receivables from the Company’s royalty partners were $3,221 and $2,223, respectively.
|